<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399971</url>
  </required_header>
  <id_info>
    <org_study_id>AAFocus</org_study_id>
    <nct_id>NCT00399971</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia</brief_title>
  <official_title>Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Zhongxing Yangfan Biotech Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The 12th Guangzhou Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liu Hua Qiao Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Zhongxing Yangfan Biotech Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that ex vivo activated immune cells would produce multiple known and
      unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell
      growth and differentiation. Additionally, these cells travel and home to bone marrow as well
      as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may
      be beneficial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be required to stay in our hospitals to receive the immunotherapy. Allogeneic
      peripheral blood mononuclear cells from healthy donors and the autologous peripheral
      mononuclear cells will alternately used for the treatment. Patients are expected to spend at
      least 6 to 12 months in the hospital and won't be released until they have improved
      significantly.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2002</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological Parameters</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic Activities in Bone Marrow</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anemia, Aplastic</condition>
  <arm_group>
    <arm_group_label>Hemathera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive cell-based immunotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ex Vivo Immunotherapy</intervention_name>
    <description>Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week</description>
    <arm_group_label>Hemathera</arm_group_label>
    <other_name>Aplastic Anemia, ex vivo Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ex vivo immunotherapy</intervention_name>
    <description>i.v. infusions, once a week, at least 6 to 12 months</description>
    <arm_group_label>Hemathera</arm_group_label>
    <other_name>Aplastic Anemia, ex vivo Immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnosis of Idiopathic Aplastic Anemia

          -  Not Eligible for Bone Marrow Transplantation

          -  Not Responsive to Conventional Immunosuppressive Therapy

        Exclusion Criteria:

          -  Leukemia or MDS or PNH or Fanconi's Disease

          -  pregnancy

          -  Allergic to Blood Product

          -  Severe Hypertension or Heart Disease

          -  Liver or Kidney Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Demao Yang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shenzhen Zhongxing Yangfan Biotech Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demao Yang, PhD</last_name>
    <phone>86 755 2603 1580</phone>
    <email>dyang@yangfan-biotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuiqing Chen, BS</last_name>
    <phone>86 755 2603 1560</phone>
    <email>info@yangfan-biotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Liu Hua Qiao Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>50010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Xiao, MD, PhD</last_name>
      <phone>86 1390 221 3175</phone>
    </contact>
    <contact_backup>
      <last_name>Yang Gao, MD</last_name>
      <phone>86 1355 618 0868</phone>
    </contact_backup>
    <investigator>
      <last_name>Jiayu Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Xiao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen J, Liu W, Wang X, Chen H, Wu J, Yang Y, Wu L, Yang D. Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematother Stem Cell Res. 2003 Oct;12(5):505-14.</citation>
    <PMID>14594507</PMID>
  </reference>
  <reference>
    <citation>Li G, Wang X, Wu L, Zhang W, Chen H, Xie Y, Yang D. Ex vivo activated immune cells promote survival and stimulate multilineage hematopoietic recovery in myelosuppressed mice. J Immunother. 2005 Jul-Aug;28(4):420-5.</citation>
    <PMID>16000962</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2006</study_first_posted>
  <last_update_submitted>November 7, 2008</last_update_submitted>
  <last_update_submitted_qc>November 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Demao Yang/Chief Scientist</name_title>
    <organization>Zhongxing Yangfan Biotech Co. Ltd.</organization>
  </responsible_party>
  <keyword>Idiopathic Aplastic Anemia</keyword>
  <keyword>Has Failed Conventional Immunosuppressive Therapy</keyword>
  <keyword>Not Eligible For Bone Marrow Transplantation</keyword>
  <keyword>C15.378.071.085</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

